Calcium and Calmodulin Signaling in Heart Failure and Arrhythmias
Please note new time 12pm
Ca is essential in cardiac electrophysiology, contraction, energetics and nuclear transcription. Calmodulin (CaM) and Ca/CaM-dependent protein kinase (CaMKII) are also important mediators of Ca signaling in myocytes. CaMKII can phosphorylate and modulate function of Na, Ca and K channels, ryanodine receptor (RyR) and IP3 receptor channels, the phospholamban-SERCA complex and myofilaments. Some of these pathways may contribute to decreased cardiac function and enhanced propensity for arrhythmias in hypertrophy and heart failure (HF). Since CaMKII expression and activation state is increased in HF, these pathways may be important in contributing to the development and consequences of HF and represent important therapeutic targets. CaMKII effects on cardiac Na channels and RyRs may be particularly important in HF and arrhythmias, and these acquired CaMKII-dependent effects can recapitulate genetic channel mutations that are associated with human long QT (LQT) and Brugada syndromes and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). In particular CaMKII can phosphorylate NaV1.5 and cause both enhanced late INa (as observed in LQT3) and also loss of Na channel availability (as in NaV1.5 mutants linked to Brugada and short QT syndromes). RyR phosphorylation by CaMKII increases diastolic sarcoplasmic reticulum (SR) Ca leak (as in CPVT-linked RyR2 mutations). This altered RyR gating can lead to increase delayed afterdepolarizations (DADs) and serve as a source of triggered arrhythmias as well as cause reduced SR Ca content available for release in HF myocytes. Thus, CaMKII activation in HF and arrhythmogenic conditions can mediate acquired forms of cardiac arrhythmias and contractile dysfunction in pathologic conditions. We have used FRET-based methods to identify fundamental changes in RyR conformation associated with pathological arrhythmogenic SR Ca leak, and this involves a loss in CaM affinity for the RyR. Dantrolene and increased CaM concentration can shift this conformational state back to normal and suppress diastolic SR Ca leak and arrhythmias. This raises the possibility of a novel RyR-related therapeutic strategy, fueling new high throughput screening approaches to identify new molecules that, like dantrolene, can shift the RyR conformational state from pathophysiological to physiological.
Date: 14 May 2019, 12:00 (Tuesday, 3rd week, Trinity 2019)
Venue: Sherrington Building, off Parks Road OX1 3PT
Venue Details: Large Lecture Theatre
Speaker: Donald M. Bers (Donald M. Bers, Ph.D. Newton-Abraham Professor, at DPAG Oxford (April-Sept 2019), Distinguished Professor & Chair Dept of Pharmacology, University of California Davis, CA, USA.)
Organising department: Department of Physiology, Anatomy and Genetics (DPAG)
Organiser contact email address:
Host: Professor David Paterson (University of Oxford)
Part of: Cardiac Sciences Theme Guest Speakers
Booking required?: Not required
Audience: Members of the University only
Editor: Talitha Smith